Several CAR-T therapies specific for different MM-associated antigens besides CD38, such as CS1, BCMA, SLAMF7, CD44v6, and CD19, proved to be effective in preclinical models and/or in clinical trials (reviewed by Morandi and colleagues [22] and Franssen and colleagues [101]). This evidence concerns the gene CD38 and Miyoshi myopathy.